A spinout of DNA2.0, the largest US-based provider of synthetic genes for industrial and academic use, Calysta Energyâs Biological Gas-to-Liquids and Biological Gas-to-Chemicals platforms allow the creation of sustainable biofuels and industrial chemicals from natural gas in order to reduce petroleum dependence without competing for food, land or water. Natural gas is one of the worldâs most abundant, economical forms of carbon, yet it is virtually untapped as a source of transportation fuels and industrial chemicals. The US has over 90 years of domestic natural gas supply at current usage rates and is expected to become a net exporter of natural gas by 2035 â in just over 20 years. The firm is developing their BioGTL and BioGTC platform technology using methane â an energy-rich component of natural gas - as a new biological feedstock for sustainable transportation fuel and industrial chemicals. Calysta leverages extensive expertise in protein engineering, gene synthesis and gene expression optimization to create advanced molecular biology tools that allow the engineering of novel production organisms, which enable process technology. While global natural gas production is expected to double in the next 30 years the technology allowing its efficient capture potential, outside of heating and electricity production, has yet to be developed on a scale compatible with most domestic applications. Calystaâs advanced bioengineering expertise allows the company to apply cutting edge technology to address a major global market opp
